Home
Live Updates
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus : vimarsana.com
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Related Keywords
Berkeley ,
California ,
United States ,
Stanford ,
Peggy Vorwald ,
Tonia Nesheiwat ,
Rachel Haurwitz ,
Mehdi Hamadani ,
Richard Lafayette ,
Steve Kanner ,
Jason Obyrne ,
Samy Figueroa ,
Globenewswire Inc ,
Caribou Biosciences Inc ,
Stanford Medicine Health Care ,
Exchange Commission ,
Nasdaq ,
College Of Wisconsin ,
Drug Administration ,
Investigational New Drug ,
Stanford Medicine Health ,
Regenerative Medicine Advanced Therapy ,
Fast Track ,
Orphan Drug ,
Private Securities Litigation Reform Act ,
Annual Report ,
Cell Therapy ,
Autoimmune Disease ,
Case Series ,
Cunninghame Graham ,
Systemic Lupus Erythematosus ,
Genetics Tell ,
Lupus Nephritis ,
Systemic Lupus ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.